Skip to main content
Qualigen Therapeutics, Inc. logo

Qualigen Therapeutics, Inc. — Investor Relations & Filings

Ticker · QLGN ISIN · US74754R1032 US Professional, scientific and technical activities
Open in API
Filings indexed 618 across all filing types
Latest filing 2016-06-06 Declaration of Voting R…
Country US United States of America
Listing US QLGN

About Qualigen Therapeutics, Inc.

https://qlgntx.com/

Qualigen Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for cancer. The company's efforts are directed toward creating therapeutics for both adult and pediatric patients, with a particular emphasis on rare cancers and areas of high unmet medical need. Its development approach combines internal capabilities with collaborations from major cancer research institutions. The company's investigational oncology pipeline includes programs such as QN-302, a Pan-RAS inhibitor platform, and QN-247.

Recent filings

Filing Released Lang Actions
Declaration of Voting Results & Voting Rights Announcements 2016
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes details about the approval of an amendment to the company's 2015 Equity Incentive Plan, voting results from the 2016 Annual Meeting of Stockholders, and the appointment of the independent registered public accounting firm. These topics correspond to changes in company plans and voting results. The document is not a full annual or quarterly report, nor is it a proxy statement or remuneration report. The key item here is the submission of matters to a vote of security holders and the voting results, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (6124 characters) and detailed voting results support this classification rather than a brief announcement or a different category.
2016-06-06 English
Capital/Financing Update 2016
Capital/Financing Update Classification · 95% confidence The document is a Post-Effective Amendment No. 2 to a Form S-1 Registration Statement filed with the SEC. It references inclusion of the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2015, and Quarterly Report on Form 10-Q for the quarter ended March 31, 2016. The document is primarily a registration statement amendment related to securities offering and includes a prospectus summary and details about the offering and company business. It is not itself an earnings release, annual report, or interim report, but rather a capital raising filing with the SEC that updates the registration statement and prospectus. The presence of the prospectus and details about shares being sold by a selling stockholder indicates this is a Capital/Financing Update. The document is lengthy (15,000 characters) and contains substantive information about the offering and company, not just a brief announcement or certification. Therefore, the best fitting category is Capital/Financing Update (CAP).
2016-06-01 English
Capital/Financing Update 2016
Capital/Financing Update Classification · 95% confidence The document is a Post-Effective Amendment No. 1 to a Form S-1 Registration Statement filed with the SEC. It includes detailed information about the company, Ritter Pharmaceuticals, and references incorporation of the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2015, and Quarterly Report on Form 10-Q for the quarter ended March 31, 2016. The document is a registration statement amendment related to securities offering and includes a prospectus summary, risk factors, and details about the selling stockholder and the offering. It is not a financial report itself but a regulatory filing related to capital raising and securities registration. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2016-05-16 English
Earnings Release 2016
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 9, 2016, by Ritter Pharmaceuticals, Inc. It reports the issuance of a press release announcing the financial results for the first quarter ending March 31, 2016. The document itself does not contain detailed financial statements or substantive financial data but rather references and furnishes the press release as an exhibit. The length of the document is 3538 characters, which is relatively short and consistent with an announcement rather than a full financial report. According to the 'Menu vs Meal' rule, this is an announcement of financial results, not the full earnings release itself. Therefore, the document should be classified as an Earnings Release (ER) since it announces quarterly financial results and provides a business update, which is typical for an earnings release announcement in an 8-K form.
2016-05-09 English
Interim / Quarterly Report 2016
Interim / Quarterly Report Q1 2016
2016-05-09 English
Proxy Solicitation & Information Statement 2016
Proxy Solicitation & Information Statement Classification · 100% confidence The document is identified as a Schedule 14A filing, which is a proxy statement pursuant to Section 14(a) of the Securities Exchange Act of 1934. It is labeled as a Definitive Additional Materials filing related to a proxy statement. Proxy statements are materials sent to shareholders to provide information and request votes for meetings. The document does not contain financial statements or earnings data, but rather information related to shareholder voting and meeting materials. Therefore, the appropriate classification is Proxy Solicitation & Information Statement (PSI). The document length is 2355 characters, which is consistent with a proxy statement or related materials rather than a full annual report or other financial report.
2016-04-21 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.